Melissa Scala, MD

  • Melissa Lewis Scala



Trabajo y Educación

Formación Profesional

Georgetown University School of Medicine, Washington, DC, 5/24/1997


University of Alabama at Birmingham, Birmingham, AL, 6/30/1999


University of Alabama at Birmingham, Birmingham, AL, 6/30/2001


Georgetown University Hospital, Washington, DC, 12/31/2012

Certificaciones Médicas

Neonatology, American Board of Pediatrics

Pediatrics, American Board of Pediatrics



Todo Publicaciones

Premature Infants Conceived with Assisted Reproductive Technology: An Analysis of Infant Morbidity, Compared with Infants Conceived Naturally. American journal of perinatology Scala, M., Berg, J., Keszler, M., Abubakar, K. 2018


OBJECTIVE: This article evaluates the morbidity of infants born via assisted reproductive technology (ART) compared with matched naturally conceived infants.STUDY DESIGN: This is a retrospective review of maternal and infant data among inborn infants conceived via ART and matched control infants born at 30 to 34 weeks' gestational age (GA) between 2006 and 2012. Data were analyzed using paired t-test or Wilcoxo-Mann-Whitney test for continuous and Fisher's exact test for categorical variables. p-Value of<0.05 was considered significant.RESULT: Of 120 study infants, 60 were conceived via ART and 60 naturally. Control infants were matched for GA, gender, race, and multiple gestations. ART infants required more respiratory support and took longer to reach full feeds compared with control infants.CONCLUSION: Infants born via ART are physiologically more immature with more intensive care needs than naturally conceived infants of similar gestation, potentially increasing health care costs. This immaturity should be considered when planning early delivery in these pregnancies.

View details for DOI 10.1055/s-0038-1667288

View details for PubMedID 30064149

Pilot study of dornase alfa (Pulmozyme) therapy for acquired ventilator-associated infection in preterm infants. Pediatric pulmonology Scala, M., Hoy, D., Bautista, M., Palafoutas, J. J., Abubakar, K. 2017


Evaluate the feasibility, safety, and efficacy of adjunctive treatment with dornase alfa in preterm patients with ventilator-associated pulmonary infection (VAPI) compared to standard care.We hypothesize that therapy with dornase alfa will be safe and well tolerated in the preterm population with no worsening of symptoms, oxygen requirement, or need for respiratory support.Prospective, randomized, blinded, pilot study comparing adjunctive treatment with dornase alfa to sham therapy. In addition to standard care, infants were randomized to receive dornase alfa 2.5mg nebulized via endotracheal tube (ETT) every 12hr for 7 days or sham therapy. ETT secretion gram stain and culture and chest X-ray (CXR) findings were evaluated. Respiratory support data were downloaded from the ventilator.Fourteen infants developed VAPI between 2012 and 2014; 11 enrolled in the study. Six received dornase alfa and five received sham therapy. Average gestational age at birth was 25 weeks and age at study entry was 31 days. There were no differences in demographics, ETT white blood cell count (WBC), CXR, or mean airway pressure (MAP) between the two groups. There was a trend towards decreased oxygen requirement (FiO2) in the treatment group that did not reach statistical significance. No side effects were observed in the treatment group.Treatment with dornase alfa is safe and treated infants had some improvement in FiO2 requirement but no improvement in MAP. A larger randomized trial is needed to evaluate the efficacy of this therapy. Pediatr Pulmonol. 2016; 9999:XX-XX. 2016 Wiley Periodicals, Inc.

View details for DOI 10.1002/ppul.23656

View details for PubMedID 28052587